Notable Upgrades: Oracle (ORCL), Apple (AAPL), Ignyta, Inc. (RXDX), T2 Biosystems (TTOO), Pandora Media (P)

Oracle Corporation (ORCL) was reiterated a ‘Buy’ by UBS analysts on Wednesday. The broker also raised its price target on the stock to $48 from $47.

On valuation measures, Oracle shares are currently priced at 18.30x this year’s forecasted earnings compared to the industry’s 34.97x earnings multiple. Ticker has a PEG and forward P/E ratio of 1.74 and 13.79, respectively. Price/Sales for the same period is 4.85 while EPS is $2.40. Currently there are 19 analysts that rate ORCL a ‘Buy’, 15 rate it a ‘Hold’. 2 analysts rate it a ‘Sell’. ORCL has a median Wall Street price target of $47.75 with a high target of $52.00.

In the past 52 weeks, shares of Redwood City, Calif.-based company have traded between a low of $35.82 and a high of $46.71 and are now at $43.99. Shares are up 13.47% year-over-year ; down 4.41% year-to-date.

Apple Inc. (AAPL) was reiterated as ‘Hold’ with a $130 from $124 price target on Wednesday by Jefferies.

Apple Inc, currently valued at $747.29 billion, has a median Wall Street price target of $145.00 with a high target of $165.00. Approximately 26.62 million shares have already changed hands, compared to the stock’s average daily volume of 57.73 million.

In the past 52 weeks, shares of the iPhone maker have traded between a low of $73.05 and a high of $133.60 with the 50-day MA and 200-day MA located at $124.50 and $111.66 levels, respectively. Additionally, shares of AAPL trade at a P/E ratio of 1.14 and have a Relative Strength Index (RSI) and MACD indicator of 58.96 and -0.13, respectively.

AAPL currently prints a one year return of about 72% and a year-to-date return of around 15.50%.

Ignyta, Inc. (RXDX) rating of ‘Outperform’ was reiterated today at Leerink Partners with a price target increase of $17 from $14 (versus a $7.92 previous close), implying 115% upside to the new price target.

RXDX shares recently gained $0.98 to $8.90. In the past 52 weeks, shares of San Diego, California-based biotech company have traded between a low of $5.36 and a high of $10.19. Shares are down 22.28% year-over-year ; up 15.62% year-to-date.

Analysts at Leerink Partners are out with a report this morning upgrading shares of T2 Biosystems, Inc. (TTOO) with a ‘Outperform‘ from ‘Market Perform‘ rating.

T2 Biosystems Inc. shares have a P/B of 6.03 and t-12 price-to-sales ratio of 2,695. EPS for the same period is ($4.14).

In the past 52 weeks, shares of Lexington, Massachusetts-based firm have traded between a low of $13.40 and a high of $24.50 and are now at $17.10. Shares are down 17.15% year-to-date.

Analysts at CRT Capital upgraded their rating on the shares of Pandora Media, Inc. (P). In a research note published on Wednesday, the firm lifted the name with a ‘Buy‘ from ‘Fair Value‘ rating and set a 12-month base case estimate of $22 from $16 per share.

On valuation measures, Pandora Media Inc. shares have a PEG and forward P/E ratio of 1.81 and 31.90, respectively. Price/Sales for the same period is 3.57 while EPS is ($0.15). Currently there are 18 analysts that rate P a ‘Buy’, 11 rate it a ‘Hold’. 1 analyst rates it a ‘Sell’. Pandora Media has a median Wall Street price target of $23.00 with a high target of $35.00.

Be the first to comment

Leave a Reply

Your email address will not be published.


*